Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Francesco Figliuolo"'
Autor:
Sabino Strippoli, Annarita Fanizzi, Davide Quaresmini, Annalisa Nardone, Andrea Armenio, Francesco Figliuolo, Raffaele Filotico, Livia Fucci, Fabio Mele, Michele Traversa, Federica De Luca, Elisabetta Sara Montagna, Eustachio Ruggieri, Simona Ferraiuolo, Francesco Macina, Stefania Tommasi, Angela Monica Sciacovelli, Ivana De Risi, Anna Albano, Raffaella Massafra, Michele Guida
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer whose incidence is growing parallel to the lengthening of the average lifespan. Cemiplimab, an antiPD-1 monoclonal antibody, is the first approved immunotherapy
Externí odkaz:
https://doaj.org/article/e3cb353df58947c7904f8a685506ef5d
Autor:
Angela Monica Sciacovelli, Elisabetta Sara Montagna, Francesco Macina, Annalisa Nardone, Raffaella Massafra, Anna Albano, Simona Ferraiuolo, Eustachio Ruggieri, Livia Fucci, Stefania Tommasi, Andrea Armenio, Federica De Luca, Ivana De Risi, Raffaele Filotico, Michele Guida, Davide Quaresmini, Francesco Figliuolo, Annarita Fanizzi, Michele Traversa, Sabino Strippoli, Fabio Mele
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
BackgroundCutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer whose incidence is growing parallel to the lengthening of the average lifespan. Cemiplimab, an antiPD-1 monoclonal antibody, is the first approved immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb418746950eac69ba6b54b43a53b68
https://www.frontiersin.org/articles/10.3389/fonc.2021.686308/full
https://www.frontiersin.org/articles/10.3389/fonc.2021.686308/full
Autor:
Federica De Luca, Francesco Figliuolo, Sabino Strippoli, Fabio Mele, Annalisa Nardone, Ruggero Filannino, Stefania Tommasi, Eustachio Ruggieri, Michele Traversa, Nicola Bartolomeo, Andrea Armenio, Ivana De Risi, Livia Fucci, Francesco Macina, Michele Guida
Publikováno v:
Cancers
Cancers, Vol 11, Iss 10, p 1559 (2019)
Cancers, Vol 11, Iss 10, p 1559 (2019)
Background: A limited degree of progression after a response to treatment is labelled as oligoprogression and is a hot topic of metastatic melanoma (MM) management. Rogue progressive metastases could benefit from local treatment, which could allow th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34dc65ad76dbad9bfdbb39836b7ce397
https://pubmed.ncbi.nlm.nih.gov/31615127
https://pubmed.ncbi.nlm.nih.gov/31615127
Autor:
Livia Fucci, Andrea Armenio, Michele Traversa, Umberto Orsini, Roberta Carbonara, Francesco Macina, Eustachio Ruggieri, Federica De Luca, Stefania Tommasi, Francesco Figliuolo, Michele Guida, Ruggero Filannino, Annalisa Nardone, Anna Albano
Publikováno v:
Clinical Practice.
The extraskeletal myxoid chondrosarcoma (EMC) is a rare malignant accounting for less than 3% of soft tissue tumors. EMC is considered an intermediate aggressive neoplasm with a slow-growing and indolent clinical course. Nevertheless, local recurrenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b13be5a76a926e2e456e8b49d09895bb
https://doi.org/10.4172/clinical-practice.1000433
https://doi.org/10.4172/clinical-practice.1000433